Oxford BioDynamics dominated the health and biotech newsflow, combining a leadership change, revenue growth, and a new US commercial partnership, though the shares fell sharply on the day. Elsewhere, Mears Group reaffirmed full-year expectations after a £1.5bn order haul, Futura Medical published encouraging pre-pivotal trial data for its female sexual dysfunction candidate, and both Poolbeg Pharma and Rua Life Sciences reported positive IP and financial milestones respectively.
Oxford BioDynamics appoints ex-Illumina executive as new CEO
Oxford BioDynamics (AIM:OBD) announced the appointment of a former Oxford Nanopore and Illumina commercial executive as its new chief executive, marking a leadership transition intended to drive the next phase of growth for the AIM-listed genomics company. The appointment coincided with news of a new US partnership and continued revenue growth, though the shares fell 33.3% to 0.1p on the day.
The combination of a CEO handover and a fresh US commercial tie-up positions Oxford BioDynamics to push harder into the American market, where genomics-based diagnostics have seen sustained institutional demand. The incoming chief executive brings direct experience scaling commercial operations at two of the sector's most prominent sequencing platforms.
Futura Medical WSD4000 data show superiority ahead of pivotal trial
Futura Medical (AIM:FUM) published positive results from two studies of its WSD4000 candidate, which is being developed as a potential first regulatory-approved over-the-counter treatment for female sexual dysfunction. The data demonstrated superiority across key measures and bolstered confidence ahead of a pivotal clinical trial the company is targeting before the end of the year. The shares rose 4.0% to 0.52p.
WSD4000 addresses a condition with no currently approved OTC option, and a successful pivotal readout would represent a significant regulatory and commercial milestone. The pre-pivotal data package now provides a stronger evidential foundation heading into that trial.
Poolbeg Pharma secures South Africa patent for POLB 001 through 2038
Poolbeg Pharma (AIM:POLB) announced the grant of a South African patent for its lead asset POLB 001, extending IP protection in that jurisdiction through to 2038. The award adds to the company's growing global intellectual property portfolio around the asset and is intended to enhance its attractiveness to prospective licensing or development partners. The shares gained 2.22% to 6.9p.
Chief Executive Jeremy Skillington framed the grant as part of a deliberate strategy to strengthen POLB 001's international IP position, with each new jurisdiction adding incremental value to the programme as the company pursues a partnering-led commercialisation path.
Rua Life Sciences swings to positive EBITDA as losses narrow
Rua Life Sciences (AIM:RUA) reported a narrowing of losses and a swing to positive EBITDA in its first-half results, with Chairman Geoff Berg pointing to a doubling of revenue over the past two years and setting out ambitions to repeat that feat over the next two. The shares rose 7.04% to 19.0p on the update.
The move into positive EBITDA marks a meaningful operational inflection for the medical device group, which develops long-term implantable polymer technologies. With the revenue base now materially larger, management's target of a further doubling carries greater absolute significance than the prior growth cycle.
